Cargando…

Preclinical and clinical phase I studies of a new recombinant Filgrastim (BK0023) in comparison with Neupogen(®)

BACKGROUND: Filgrastim or methionyl-granulocyte colony-stimulating factor (Met-G-CSF), is a recombinant therapeutic protein widely used to treat severe neutropenia caused by myelosuppressive drugs in patients with nonmyeloid malignancies. In addition to its role in the regulation of granulopoiesis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crobu, Davide, Spinetti, Gaia, Schrepfer, Rodolfo, Tonon, Giancarlo, Jotti, Gloria Saccani, Onali, Pierluigi, Dedoni, Simona, Orsini, Gaetano, Di Stefano, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942296/ https://www.ncbi.nlm.nih.gov/pubmed/24555723 http://dx.doi.org/10.1186/2050-6511-15-7

Ejemplares similares

High-level expression of a recombinant active microbial transglutaminase in Escherichia coli
por: Salis, Barbara, et al.
Publicado: (2015)

Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes
por: Selis, Fabio, et al.
Publicado: (2012)

Effectiveness and Safety of Filgrastim (Neupogen™) versus Filgrastim-aafi (Nivestim™) in Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia: An Observational Cohort Study
por: Al-Rabayah, Abeer A., et al.
Publicado: (2022)

PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers
por: Yao, Hsuan-Ming, et al.
Publicado: (2019)

Valproic acid upregulates the expression of the p75NTR/sortilin receptor complex to induce neuronal apoptosis
por: Dedoni, Simona, et al.
Publicado: (2020)

The Neurotrophin Receptor TrkC as a Novel Molecular Target of the Antineuroblastoma Action of Valproic Acid
por: Dedoni, Simona, et al.
Publicado: (2021)

Pegylated Trastuzumab Fragments Acquire an Increased in Vivo Stability but Show a Largely Reduced Affinity for the Target Antigen
por: Selis, Fabio, et al.
Publicado: (2016)

Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015)

EHMTI-0023. Characteristics of post-traumatic headache following mild traumatic brain injury in military personnel in Iran
por: Jouzdani, S Rezaei, et al.
Publicado: (2014)

Filgrastim, fibrinolysis, and neovascularization
por: Eton, Darwin, et al.
Publicado: (2022)

Neupogen and mesenchymal stem cells are the novel therapeutic agents in regeneration of induced endometrial fibrosis in experimental rats
por: Sabry, Dina, et al.
Publicado: (2017)

Innovator Filgrastim versus Generic Filgrastim in Hematopoietic Stem Cell Transplantation Mobilization
por: Husian, Sadik, et al.
Publicado: (2021)

Ectopic Expression of Rv0023 Mediates Isoniazid/Ethionamide Tolerance via Altering NADH/NAD(+) Levels in Mycobacterium smegmatis
por: Gupta, Shailesh Kumar, et al.
Publicado: (2020)

Efficacy and Safety of Nivestim Versus Neupogen for Mobilization of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation
por: Chew, Cindy, et al.
Publicado: (2019)

The Safety Profile of Filgrastim and Pegfilgrastim
por: Neumann, Theresa A., et al.
Publicado: (2011)

Chemotherapy-Induced Neutropenia in HIV Positive Patients with Lymphoma: Comparison of Pegfilgrastim with Daily Filgrastim Administration
por: Teofili, Luciana, et al.
Publicado: (2012)

Upregulation of p75NTR by Histone Deacetylase Inhibitors Sensitizes Human Neuroblastoma Cells to Targeted Immunotoxin-Induced Apoptosis
por: Dedoni, Simona, et al.
Publicado: (2022)

Biosimilars in the management of neutropenia: focus on filgrastim
por: Caselli, Désirée, et al.
Publicado: (2016)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Filgrastim associations with CAR T‐cell therapy
por: Gaut, Daria, et al.
Publicado: (2020)

Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Biosimilar filgrastim vs filgrastim: a multicenter nationwide observational bioequivalence study in patients with chemotherapy-induced neutropenia
por: Sevinç, Alper, et al.
Publicado: (2018)

Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial
por: Waller, Cornelius F., et al.
Publicado: (2010)

Incidence of febrile neutropenia during chemotherapy among patients with nonmyeloid cancer receiving filgrastim vs a filgrastim biosimilar
por: Schwartzberg, Lee S, et al.
Publicado: (2018)

The Real-World Experience of the Biosimilar (Grastofil(®)) to the Reference Biologic (Neupogen(®)) in Breast Cancer and Lymphoma: A Canadian Single-Centre Retrospective Study
por: Wong, Gina, et al.
Publicado: (2022)

Photoconversion and Fluorescence Properties of a Red/Green-Type Cyanobacteriochrome AM1_C0023g2 That Binds Not Only Phycocyanobilin But Also Biliverdin
por: Fushimi, Keiji, et al.
Publicado: (2016)

Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia
por: Kamioner, Didier, et al.
Publicado: (2013)

Effect of Preoperative Inflammatory Status and Comorbidities on Pain Resolution and Persistent Postsurgical Pain after Inguinal Hernia Repair
por: Bugada, Dario, et al.
Publicado: (2016)

Filgrastim therapy in a child with neutropenia induced by linezolid
por: Hernández Segurado, Marta, et al.
Publicado: (2013)

The Use of Filgrastim in Patients with Hodgkin Lymphoma Receiving ABVD
por: Binder, Adam F., et al.
Publicado: (2017)

Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy
por: Schwartzberg, Lee S., et al.
Publicado: (2018)

Long-term safety of filgrastim (rhG-CSF) administration
por: Confer, Dennis L, et al.
Publicado: (2007)

Acute Myocardial Infarction Caused by Filgrastim: A Case Report
por: Bilir, Cemil, et al.
Publicado: (2012)

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
por: Dale, David C., et al.
Publicado: (2017)

Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients
por: Johannesen, Siw, et al.
Publicado: (2018)

Quality Comparison of Biosimilar and Copy Filgrastim Products with the Innovator Product
por: Halim, Liem Andhyk, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Effect of Filgrastim on adult male rats’ fertility and reproductive performance
por: Saber, Sara Mohamed, et al.
Publicado: (2021)

Days of Prophylactic Filgrastim Use to Reduce Febrile Neutropenia in Patients
por: Scott, Shane J., et al.
Publicado: (2003)

A phase III, randomized, non-inferiority study comparing the efficacy and safety of biosimilar filgrastim versus originator filgrastim for chemotherapy-induced neutropenia in breast cancer patients
por: Hegg, Roberto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_40pdfod6gfbl7sb7n1as0tcu3n